Sweden’s NEOGAP Therapeutics Receives €500K Grant to Advance Personalized Cancer Immunotherapy Analysis

NEOGAP Therapeutic has secured nearly €500K in funding from Eurostars for a collaboration project with the French biotech company Okomera. NEOGAP is developing pTTL, a personalized cell therapy utilizing modified proteins to activate the immune system against cancer cells, currently undergoing Phase I/II clinical trials for colorectal cancer.